|Almut Winterstein, RPh, Ph.D., FISPE
Professor and Chair
Office: HPNP Room 3336
|Dr. Winterstein’s research program focuses on the evaluation and prediction of drug safety and effectiveness in real-world populations and on devising ways to improve medication use. Clinical areas of interest include pediatrics and pregnancy, psychopharmacology and treatment and prevention of infectious disease.|
|Joshua Brown, Pharm.D., Ph.D., M.S.
Assistant Professor and Associate Graduate Program Director
Office: HPNP 3320
|Dr. Brown’s research is in the field of comparative effectiveness and safety research focusing on anticoagulants, hematology and cardiology, and in health care policy evaluation|
|Vakaramoko Diaby, Ph.D., M.Sc.
Office: HPNP Room 3317
|Dr. Diaby’s research interests are in the field of economic evaluation, decision analytic modeling, health technology assessment, or HTA, and priority setting using multi-criteria decision analysis, or MCDA.|
|Randy Hatton, Pharm.D, BPharm, FCCP, BCPS
Office: HPNP Room 2331
|Dr. Hatton’s research interests include evidence-based practice, patient safety and over-the-counter products.|
|Juan Hincapie-Castillo, Pharm.D., M.S., Ph.D.
Office: HPNP Room 2338
|Dr. Hincapie-Castillo’s research interests include pharmacoepidemiology, drug utilization and safety in pain management, health services research and legal epidemiology, as well as patient safety and quality of inpatient pain management|
|Wei-Hsuan “Jenny” Lo-Ciganic, M.S.Pharm, M.S., Ph.D.
Office: HPNP Room 3319
|Dr. Lo-Ciganic’s research program focuses on evaluation of treatment effectiveness and safety, application of advanced predictive analytics, and improvement of prescribing quality and health disparity, especially among vulnerable populations. Areas of research interests include medication adherence, prescription drug abuse, treatment for substance use disorders, chronic diseases management and oncology.|
|Robert P. Navarro, Pharm.D.
Office: HPNP 2338
|Dr. Navarro’s research interests include real-world drug value assessments, performance-based risk-sharing arrangements with pharmaceutical manufacturers and value-based drug formulary management in various patient populations, as well as benefits and risks of public pharmaceutical policy on patient drug access, affordability and outcomes experiences.|
|Haesuk Park, Ph.D.
Office: HPNP Room 3325
|Dr. Park’s research program focuses on the evaluation of economic and health outcomes of medications and pharmaceutical care services as well as policy associated with the use of pharmaceuticals.|
|Richard Segal, Ph.D.
Associate Dean, Professor, and Graduate Program Director
Office: HPNP Room 4332C
|Dr. Segal’s research focuses on improving the quality and safety of the medication use process, with a particular emphasis on improving prescribing practices and in creating collaborative practice models to improve medication use by patients|
|Scott Vouri, Pharm.D.
Office: HPNP 3324
|Dr. Vouri’s research interests include pharmacoepidemiology and pharmaceutical health services research related to the fields of inappropriate medication prescribing/deprescribing, geriatrics, urology, and medication utilization following bariatric surgery.|
|Yu-Jung “Jenny” Wei, Ph.D.
Office: HPNP 3321
|Dr. Wei’s research programs focus on questions surrounding the effectiveness, safety and quality of medication use in elderly patients with chronic conditions, especially those in nursing home settings.|